| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30082786 | HIV | ENSG00000105464.4 | protein_coding | GRIN2D | No | No | 2906 | O15399 |
| TVIS30049065 | HIV | ENSG00000105464.4 | protein_coding | GRIN2D | No | No | 2906 | O15399 |
| TVIS30049066 | HIV | ENSG00000105464.4 | protein_coding | GRIN2D | No | No | 2906 | O15399 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | GRIN2D |
|---|---|
| DrugBank ID | DB00142 |
| Drug Name | Glutamic acid |
| Target ID | BE0000396 |
| UniProt ID | O15399 |
| Regulation Type | |
| PubMed IDs | 17139284; 17016423; 11755246; 8886398; 9417820 |
| Citations | Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.@@Pliss L, Jezova D, Mares V, Balcar VJ, St'astny F: N-Acetyl-L-aspartyl-L-glutamate changes functional and structural properties of rat blood-brain barrier. Neurosci Lett. 2002 Jan 11;317(2):85-8.@@Bresink I, Benke TA, Collett VJ, Seal AJ, Parsons CG, Henley JM, Collingridge GL: Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cells. Br J Pharmacol. 1996 Sep;119(2):195-204.@@Sundstrom E, Whittemore S, Mo LL, Seiger A: Analysis of NMDA receptors in the human spinal cord. Exp Neurol. 1997 Dec;148(2):407-13. |
| Groups | Approved; Nutraceutical |
| Direct Classification | Glutamic acid and derivatives |
| SMILES | N[C@@H](CCC(O)=O)C(O)=O |
| Pathways | Histidinemia; Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency); 3-Methylglutaconic Aciduria Type I; beta-Ketothiolase Deficiency; Purine Nucleoside Phosphorylase Deficiency; Tyrosine Metabolism; Ketoprofen Action Pathway; Glutamate Metabolism; Argininosuccinic Aciduria; Salla Disease/Infantile Sialic Acid Storage Disease; Tyrosinemia Type I; Hyperinsulinism-Hyperammonemia Syndrome; 2-Methyl-3-hydroxybutryl-CoA Dehydrogenase Deficiency; Glutaric Aciduria Type I; Propanoate Metabolism; Celecoxib Action Pathway; Glycine and Serine Metabolism; Suprofen Action Pathway; Indomethacin Action Pathway; Carbamoyl Phosphate Synthetase Deficiency; Sialuria or French Type Sialuria; Ibuprofen Action Pathway; Saccharopinuria/Hyperlysinemia II; Histidine Metabolism; Arginine and Proline Metabolism; Purine Metabolism; Diflunisal Action Pathway; Etodolac Action Pathway; Ammonia Recycling |
| PharmGKB | PA449776 |
| ChEMBL | CHEMBL575060 |
